Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMP 110

Next Previous
Drug Profile

AMP 110

Alternative Names: AMP-110

Latest Information Update: 30 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amplimmune
  • Developer AstraZeneca; Daiichi Sankyo Company
  • Class Antirheumatics; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action V-set domain-containing T-cell activation inhibitor 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 30 Jun 2026 Discontinued - Phase-I for Rheumatoid arthritis in USA (IV)
  • 30 Jun 2026 Discontinued - Preclinical for Autoimmune disorders in USA (IV)
  • 28 Nov 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top